The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
A systematic review of the international prevalence of BRCA mutation in breast cancer
Open accessAbstract
Abstract: A systematic review was conducted, summarizing international BRCA 1 or 2 ( BRCA1/2 ) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1–9% on immunohistochemistry/human epidermal growth factor receptor 2–negative [HER2-]) breast cancer. In 2 large studies unselected for family history, ethnicity, sex, or age and no/unclear selection by breast cancer stage or hormone receptor (HR) status, germline BRCA (g BRCA ) mutation prevalence was 2.9% (Italy) to 3.0% (South Korea). In the 4 large unselected triple-negative breast cancer studies, g BRCA mutation prevalence varied from 9.3% (Australia) to 15.4% (United States). g BRCA mutation prevalence in 1 large unselected HR positive/HER2- early breast cancer study was 5% (United States). In 2 large unselected metastatic breast cancer studies, g BRCA mutation prevalence was 2.7% (France) and 4.3% (Germany). Locally advanced breast cancer studies were small and not in unselected populations. Poor reporting of g BRCA status and basis of selection implies a need for further large well-reported BRCA mutation prevalence studies in breast cancer. Keywords: BRCA1, BRCA2, prevalence, systematic review, chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Munn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
(2015) · Annals of Oncology · doi:10.1093/annonc/ · Cited by 733
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Gudmundsdottir, K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 622
Tung, N., Lin, N. U., Kidd, J., Allen, B. A., Singh, N., Wenstrup, R. J., Hartman, A.-R., Winer, E. P., & Garber, J. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.0747 · Cited by 556
Tung, N., Battelli, C., Allen, B., Kaldate, R., Bhatnagar, S., Bowles, K., Timms, K., Garber, J. E., Herold, C., Ellisen, L., et al. (2015) · Cancer · doi:10.1002/cncr.29010 · Cited by 430
Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L., Saam, J., Lancaster, J., & Daly, M. B. (2017) · Cancer · doi:10.1002/cncr.30498 · Cited by 399
Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., & Katz, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01854 · Cited by 387
Susswein, L. R., Marshall, M. L., Nusbaum, R., Vogel Postula, K. J., Weissman, S. M., Yackowski, L., Vaccari, E. M., Bissonnette, J., Booker, J. K., Cremona, M. L., et al. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.166 · Cited by 287
PARP inhibitors in the management of breast cancer: current data and future prospects
Livraghi, L., & Garber, J. E. (2015) · BMC Medicine · doi:10.1186/s12916-015-0425-1 · Cited by 269
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer
Kast, K., Rhiem, K., Wappenschmidt, B., Hahnen, E., Hauke, J., Bluemcke, B., Zarghooni, V., Herold, N., Ditsch, N., Kiechle, M., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103672 · Cited by 230
Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
Hartman, A., Kaldate, R. R., Sailer, L. M., Painter, L., Grier, C. E., Endsley, R. R., Griffin, M., Hamilton, S. A., Frye, C. A., Silberman, M. A., et al. (2012) · Cancer · doi:10.1002/cncr.26576 · Cited by 220
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., Elia, M., Connor, C. S., McGinness, M. K., Mammen, J. M. W., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2980-0 · Cited by 201
Weitzel, J. N., Clague, J., Martir-Negron, A. E., Ogaz, R., Herzog, J., Ricker, C. N., Jungbluth, C. R., Cina, C., Duncan, P. R., Unzeitig, G. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0027 · Cited by 152
Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer
Wong‐Brown, M. W., Meldrum, C. J., Carpenter, J., Clarke, C. L., Narod, S. A., Jakubowska, A., Rudnicka, H., Lubiński, J., & Scott, R. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3293-7 · Cited by 126
NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine
Valerie, N. C. K., Hagenkort, A., Page, B. D. G., Masuyer, G., Rehling, D., Carter, M., Bevc, L., Herr, P., Homan, E. J., Gustafsson, N., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0584 · Cited by 125
A high frequency of BRCA mutations in young black women with breast cancer residing in Florida
Pal, T., Bonner, D. E., Cragun, D. L., Monteiro, Á. N. A., Phelan, C., Servais, L., Kim, J., Narod, S. A., Akbari, M. R., & Vadaparampil, S. T. (2015) · Cancer · doi:10.1002/cncr.29645 · Cited by 118
Korean Hereditary Breast Cancer Study Group, Kang, E., Seong, M., Park, S. S., Lee, J. W., Lee, J., Kim, L. S., Lee, J. E., Kim, S. Y., Jeong, J., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3377-4 · Cited by 112
Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T. M., Srimuninnimit, V., Pittman, K. B., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx075 · Cited by 107
Sanford, R. A., Song, J., Gutierrez‐Barrera, A. M., Profato, J., Woodson, A., Litton, J. K., Bedrosian, I., Albarracin, C. T., Valero, V., & Arun, B. (2015) · Cancer · doi:10.1002/cncr.29572 · Cited by 101
Stadler, Z. K., Salo‐Mullen, E. E., Patil, S. M., Pietanza, M. C., Vijai, J., Saloustros, E. S., Hansen, N. A. L., Kauff, N. D., Kurtz, R. C., Kelsen, D. P., et al. (2011) · Cancer · doi:10.1002/cncr.26191 · Cited by 98
TNT Trial TMG, B. (., Robertson, L. B., Hanson, H., Seal, S., Warren-Perry, M., Hughes, D., Howell, I., Turnbull, C., Houlston, R. S., Shanley, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.31 · Cited by 97
Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis
Felice, F. D., Marchetti, C., Musella, A., Palaia, I., Perniola, G., Musio, D., Muzii, L., Tombolini, V., & Panici, P. B. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4532-1 · Cited by 92
Breast Cancer Risks and Risk Prediction Models
Engel, C., & Fischer, C. (2015) · Breast Care · doi:10.1159/000376600 · Cited by 68
Paluch–Shimon, S., Friedman, E., Berger, R., Papa, M. Z., Dadiani, M., Friedman, N., Shabtai, M., Zippel, D. B., Gutman, M., Golan, T., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3800-5 · Cited by 58
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer
Rummel, S. K., Varner, E. L., Shriver, C. D., & Ellsworth, R. E. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2348-2 · Cited by 57
Korean Breast Cancer Study Group, Kim, H., Cho, D.-Y., Choi, D. H., Choi, S., Shin, I., Park, W., Huh, S. J., Han, S. H., Lee, M. H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2159-5 · Cited by 53
Risk of having BRCA1 mutation in high‐risk women with triple‐negative breast cancer: a meta‐analysis
Tun, N. M., Villani, G. M., Ong, K., Yoe, L., & Bo, Z. (2013) · Clinical Genetics · doi:10.1111/cge.12270 · Cited by 53
Lolas Hamameh, S., Renbaum, P., Kamal, L., Dweik, D., Salahat, M., Jaraysa, T., Abu Rayyan, A., Casadei, S., Mandell, J. B., Gulsuner, S., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30771 · Cited by 42
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations
Bayraktar, S., Gutierrez‐Barrera, A. M., Lin, H. Y., Elsayegh, N., Tasbas, T., Litton, J. K., Ibrahim, N. K., Morrow, P. K. H., Green, M., Valero, V., et al. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9567-8 · Cited by 38
González‐Rivera, M., Lobo, M., López‐Tarruella, S., Jerez, Y., del Monte-Millán, M., Massarrah, T., Ramos‐Medina, R., Ocaña, I., Picornell, A. C., Garzón, S. S., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3792-1 · Cited by 38
Pal, T., Bonner, D. E., Kim, J., Monteiro, Á. N. A., Kessler, L. J., Royer, R., Narod, S. A., & Vadaparampil, S. T. (2013) · The Breast Journal · doi:10.1111/tbj.12083 · Cited by 37
Genetic testing in a cohort of young patients with HER2-amplified breast cancer
Eccles, D., Li, N., Handwerker, R., Maishman, T., Copson, E., Durcan, L., Gerty, S., Jones, J. L., Evans, D. G., Haywood, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv592 · Cited by 23
BRCA sequencing and large rearrangement testing in young Black women with breast cancer
Pal, T., Bonner, D. E., Cragun, D. L., Johnson, S., Akbari, M. R., Servais, L., Narod, S. A., & Vadaparampil, S. T. (2013) · Journal of Community Genetics · doi:10.1007/s12687-013-0166-9 · Cited by 18
Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
Palomba, G., Budroni, M., Olmeo, N. A., Atzori, F., Ionta, M. T., Pisano, M., Tanda, F., Cossu, A., & Palmieri, G. (2014) · Oncology Letters · doi:10.3892/ol.2014.1834 · Cited by 18
Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer
Emborgo, T. S., Saporito, D., Muse, K. I., Gutierrez‐Barrera, A. M., Litton, J. K., Lu, K. H., & Arun, B. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa002 · Cited by 14
Yoon, K., Park, B., Lee, B. I., Yang, M. J., Kong, S., & Lee, E. S. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2016.292 · Cited by 13
Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario.
Vanstone, M. G., Chow, W., Lester, L., Ainsworth, P., Nisker, J., & Brackstone, M. (2012) · Europe PMC (PubMed Central) · Cited by 12
Multigene panel testing results in patients with multiple breast cancer primaries
Corredor, J. L., Woodson, A., Gutierrez‐Barrera, A. M., & Arun, B. (2020) · The Breast Journal · doi:10.1111/tbj.13762 · Cited by 9
Asleh, K., & Fried, G. (2015) · SpringerPlus · doi:10.1186/s40064-015-0900-3 · Cited by 8
Dagan, E., Gershoni‐Baruch, R., Kurolap, A., & Fried, G. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12594 · Cited by 6
Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing
Cruz, J. D. L., André, F., Harrell, R. K., Bassett, R. L., Arun, B., Mathieu, M., Delaloge, S., & Gilcrease, M. Z. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.02.002 · Cited by 5
Cited by
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Pashayan, N., Antoniou, A. C., Ivanus, U., Esserman, L. J., Easton, D. F., French, D., Sroczynski, G., Hall, P., Cuzick, J., Evans, D. G., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0388-9 · Cited by 438
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393
Multiple imputation with missing data indicators.
Beesley, L. J., Bondarenko, I., Elliot, M. R., Kurian, A. W., Katz, S. J., & Taylor, J. M. (2021) · Statistical Methods in Medical Research · doi:10.1177/09622802211047346 · Cited by 114
Senkus, E., Delaloge, S., Domchek, S. M., Conte, P., Im, S., Xu, B., Armstrong, A., Masuda, N., Fielding, A., Robson, M., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34525 · Cited by 39
Metadata
- Authors
- Armstrong, N., Ryder, S., Forbes, C., Ross, J., & Quek, R. G.
- Venue
- Clinical Epidemiology
- Publisher
- Informa UK Limited
- Published
- 2019-07
- Volume
- Volume 11
- Pages
- 543-561
- ISSN
- 1179-1349 (ISSN-L)
- OpenAlex
- W2957101013
- Cited by
- 259
- References
- 50
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.